肝脏靶向性基因治疗的研究进展

摘要/Abstract

摘要： 基因治疗是一种通过载体系统将目的基因导入机体发挥治疗作用的新型药物。肝脏靶向性基因治疗不仅可以针对肝脏本身疾病发挥作用，还可利用肝脏作为机体的生物反应器，通过表达的基因产物对全身性或其他器官的疾病发挥治疗作用。由于肝脏具有对进入体内物质的代谢和解毒特性，大多数基因载体都会进入肝脏。因此肝脏靶向性是基因治疗领域的一个重要研究方向。早期由于特异性、疗效、毒性和免疫限制，肝脏靶向性基因治疗的实际临床价值受到限制。随着载体技术和监测技术的不断进步，肝脏靶向性基因治疗现已成为治疗各种肝脏和非肝脏相关疾病的一种具有潜力的方法。本研究在梳理肝脏靶向性基因治疗分类、病毒和非病毒载体系统的基础上，概述肝脏靶向性基因治疗技术进展过程和发展现状，探讨肝脏靶向性基因治疗在肝癌、遗传性系统性疾病、遗传性代谢性肝病、脂代谢紊乱性疾病等方面应用，总结分析当前肝脏靶向性基因治疗存在问题以及潜在解决方案，进一步展望肝脏靶向性基因治疗的未来前景，以期为肝脏靶向性基因治疗的研究和应用提供借鉴和参考，进而促进我国基因治疗的创新发展。

关键词: font-size:medium, ">基因治疗；肝脏靶向性；病毒载体；非病毒载体

Abstract: Gene therapy is a new drug that introduces target genes into the body through a vector system to exert therapeutic effects. Liver-targeted gene therapy can not only target liver diseases， but also utilize the liver as a bioreactor to treat systemic or other organ diseases through expressed gene products. Due to the liver′s ability tometabolize and detoxify substances entering the body， most of gene vectors enter the liver. Therefore， liver-targeted is an important research direction in the field of gene therapy. In the early stage， due to specificity， efficacy， toxicity， and immune limitation， the practical clinical value of liver-targeted gene therapy is limited. However， with the continuous progress of vector technology and monitoring technology， liver-targeted gene therapy has become a promising method for treating various liver and non liver related diseases. On the basis of reviewing the classification of liver-targeted gene therapy， viral and non-viral vector systems， this review summarized the progress and current status of liver-targeted gene therapy technology， explored the application of liver-targeted gene therapy in liver cancer， hereditary systemic diseases， hereditary metabolic liver diseases， lipid metabolism disorders， and other aspects， and also summarized and analyzed the current problems and potential solutions of liver-targeted gene therapy， and further looked forword to the future prospects of liver-targeted gene therapy， in order to provide insights for the research and application of liver-targeted gene therapy， and thereby promote the development of gene therapy.

Key words: Gene therapy, Liver-targeted, Viral vector, Non-viral vector

中图分类号:

刘国庆, 时斯婧, 杨钧婷, 陶怡君, 宋国华, 王宇辉. 肝脏靶向性基因治疗的研究进展[J]. 中国医药导刊, 2023, 25(9): 881-890.

LIU Guoqing, SHI Sijing, YANG Junting, TAO Yijun, SONG Guohua, WANG Yuhui. Research Progress in Liver-Targeted Gene Therapy[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(9): 881-890.

参考文献

[1]Schulte S.Innovative coagulation factors：albumin fusion technology and recombinant single-chain factor Ⅷ[J]. Thromb Res，2013，131 (Suppl 2)：S2-6.
     [2]Lechowicz U，Rudzinski S， Jezela-Stanek A，et al. Post-translational modifications of circulating Alpha-1-Antitrypsin protein[J]. Int J Mol Sci， 2020， 21(23)：9187-9205.
     [3]Collins CJ，Yi F，Dayuha R，et al. Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease[J]. Gastroenterology， 2021，160(7)： 2367-2382.
     [4]Chen Z，Chen L，Sun B，et al. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway[J]. Mol Metab， 2021， 51：101230.
     [5]Thompson WL， Takbe T. Human liver model systems in a dish[J]. Dev Growth Differ，2021， 63(1)： 47-58.
     [6]Mishra AR， Zheng J， Tang X， et al. Silver nanoparticle-induced autophagic-lysosomal disruption and NLRP3-inflammasome activation in HepG2 cells is size-dependent[J]. Toxicol Sci，2016，150(2)： 473-487.
     [7]Palaschak B， Herzog RW， Markusic DM. AAV-mediated gene delivery to the liver：overview of current technologies and methods[J]. Methods Mol Biol，2019，1950：333-360.
     [8]Jin Y，Wang H，Yi K，et al. Applications of nanobiomaterials in the therapy and imaging of acute liver failure[J]. Nanomicro Lett，2020，13(1)： 25.
     [9]Serrano-Mendioroz I，Sampedro A，Serna N，et al. Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria[J]. Hum Mol Genet，2018， 27(21)： 3688-3696.
     [10]Richards DY，Winn SR，Dudley S，et al. AAV-mediated CRISPR/Cas9 gene editing in murine phenylketonuria[J]. Mol Ther Methods Clin Dev，2020，17：234-245.
     [11]Wang L，Warzecha CC，Kistner A，et al. Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression[J]. Mol Ther Methods Clin Dev， 2022， 24：292-305.
     [12]De Mattia E，Cecchin E，Polesel J，et al. UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population[J]. Liver Int，2017， 37(9)： 1345-1353.
     [13]Hegele RA，Tsimikas S.Lipid-lowering agents[J]. Circ Res，2019，124(3)：386-404.
     [14]Ferla R，Alliegro M，Marteau JB，et al. Non-clinical safety and efficacy of an AAV2/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI[J]. Mol Ther Methods Clin Dev，2017， 6：143-158.
     [15]Alves-Bezerra M，Furey N，Johnson CG，et al. Using CRISPR/Cas9 to model human liver disease[J]. JHEP Rep，2019，1(5)：392-402.
     [16]Uddin F， Rudin CM， Sen T.CRISPR gene therapy：applications，limitations，and implications for the future[J]. Front Oncol，2020，10：1387.
     [17]Xu T，Li L，Liu YC，et al. CRISPR/Cas9-related technologies in liver diseases：from feasibility to future diversity[J]. Int J Biol Sci，2020，16(13)： 2283-2295.
     [18]Gong J，Wang HX，Lao YH，et al. A versatile nonviral delivery system for multiplex gene-editing in the liver[J]. Adv Mater，2020，32(46)： e2003537.
     [19]Wei L，Chiu DK，Tsang FH，et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3[J]. J Hepatol，2017， 67(4)： 758-769.
     [20]Pott LL，Hagemann S，Reis H，et al. Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC[J]. Oncotarget，2017， 8(7)： 11950-11962.
     [21]He J，Zhang W，Li A，et al. Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition[J]. Biochem Biophys Res Commun，2018，500(2)：177-183.
     [22]Wang X，Zhang W，Ding Y，et al. CRISPR/Cas9-mediated genome engineering of CXCR4 decreases the malignancy of hepatocellular carcinoma cells in vitro and in vivo[J]. Oncol Rep，2017， 37(6)： 3565-3571.
     [23]Iwagami Y，Huang CK，Olsen MJ，et al. Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma[J]. Hepatology，2016，63(4)：1213-1226.
     [24]Chen H，Shi M，Gilam A，et al. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human factor Ⅷ [J]. Sci Rep，2019，9(1)： 16838.
     [25]Qi Y，Gao Z，Xu G，et al. DNA polymerase κ is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus[J]. PLoS Pathog，2016，12(10)： e1005893.
     [26]Price AA，Sampson TR，Ratner HK，et al. Cas9-mediated targeting of viral RNA in eukaryotic cells[J]. Proc Natl Acad Sci USA，2015，112(19)： 6164-6169.
     [27]Crooke ST， Geary RS.Clinical pharmacological properties of mipomersen (Kynamro)，a second generation antisense inhibitor of apolipoprotein B[J]. Br J Clin Pharmacol，2013，76(2)： 269-276.
     [28]Deng M，Kutrolli E，Sadewasser A，et al. ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy[J]. J Lipid Res，2022，63(7)： 100237.
     [29]RekiC D，Azarov I，Knchel J，et al. AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval[J]. Br J Clin Pharmacol，2022，88(11)：4839-4844.
     [30]Witztum JL，Gaudet D，Freedman SD，et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome[J]. N Engl J Med，2019，381(6)：531-542.
     [31]Gouni-Berthold I，Alexander VJ，Yang Q，et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS)：a multicentre， double-blind， randomised， placebo-controlled， phase 3 trial[J]. Lancet Diabetes Endocrinol，2021，9(5)：264-275.
     [32]Dong Y，Siegwart DJ，Anderson DG.Strategies，design，and chemistry in siRNA delivery systems[J]. Adv Drug Deliv Rev，2019，144：133-147.
     [33]Zhang X，Goel V，Attarwala H，et al. Patisiran pharmacokinetics，pharmacodynamics，and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis[J]. J Clin Pharmacol，2020，60(1)：37-49.
     [34]Ragusa R，Basta G，Neglia D，et al. PCSK9 and atherosclerosis：looking beyond LDL regulation[J]. Eur J Clin Invest，2021，51(4)：e13459.
     [35]Jang AY，Lim S，Jo SH，et al. New trends in dyslipidemia treatment [J]. Circ J，2021，85(6)：759-768.
     [36]Akoumianakis I，Zvintzou E，Kypreos K，et al. ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets[J]. Curr Atheroscler Rep，2021，23(5)：20.
     [37]Liu W，Iwamoto N，Marappan S，et al. Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference[J]. Nucleic Acids Res，2023，51(9)：4126-4147.
     [38]Zhao Y，Zhang X，Liu Y，et al. Inhibition of ALAS1 activity exerts anti-tumour effects on colorectal cancer in vitro[J]. Saudi J Gastroenterol，2020，26(3)：144-152.
     [39]Russell S，Bennett J，Wellman JA，et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy：a randomised， controlled，open-label，phase 3 trial [J]. Lancet，2017，390(10097)： 849-860.
     [40]Ginocchio VM，Ferla R，Auricchio A，et al. Current status on clinical development of adeno-associated virus-mediated liver-directed gene therapy for inborn errors of metabolism[J]. Hum Gene Ther，2019，30(10)：1204-1210.
     [41]Tabebordbar M，Lagerborg KA，Stanton A，et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species[J]. Cell，2021，184(19)：4919-4938.e22.
     [42]Hwang JH，Lee S，Kim E，et al. Heparin-coated superparamagnetic nanoparticle-mediated adeno-associated virus delivery for enhancing cellular transduction[J]. Int J Pharm，2011，421(2)：397-404.
     [43]Seppen J，Bakker C，De Jong B，et al. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats[J]. Mol Ther，2006， 13(6)：1085-1092.
     [44]Logan GJ，Dane AP，Hallwirth CV，et al. Identification of liver-specific enhancer-promoter activity in the 3′ untranslated region of the wild-type AAV2 genome[J]. Nat Genet，2017，49(8)：1267-1273.
     [45]Buck TM，Wijnhold J. Recombinant adeno-associated viral vectors (rAAV)-vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays[J]. Int J Mol Sci，2020，21(12)： 4197.
     [46]Hareendran S，Balakrishnan B，Sen D，et al. Adeno-associated virus (AAV) vectors in gene therapy：immune challenges and strategies to circumvent them[J]. Rev Med Virol，2013，23(6)：399-413.
     [47]Dai X，Wu L，Sun R，et al. Atomic structures of minor proteins Ⅵ and Ⅶ in human adenovirus[J]. J Virol，2017，91(24)： e00850-17.
     [48]PodgorskI Ⅱ，Harrach B，Benk M，et al. Characterization of monkey adenoviruses with three fiber genes[J]. Infect Genet Evol，2023，108：105403.
     [49]Milone MC，O′doherty U.Clinical use of lentiviral vectors[J]. Leukemia，2018，32(7)：1529-1541.
     [50]Ediriweera GR，Chen L，Yerbury J， et al. Non-viral vector-mediated gene therapy for ALS：challenges and future perspectives[J]. Mol Pharm，2021，18(6)： 2142-2160.
     [51]Tasset A，Bellamkonda A，Wang W，et al. Overcoming barriers in non-viral gene delivery for neurological applications[J]. Nanoscale，2022，14(10)： 3698-3719.
     [52]Arbuthnot P，Ely A，Weinberg MS.Hepatic delivery of RNA interference activators for therapeutic application[J]. Curr Gene Ther，2009，9(2)： 91-103.
     [53]Serafini P，Villanueva-antolí A，Adhikari SD，et al. Increasing the performance and stability of red-light-emitting diodes using guanidinium mixed-cation perovskite nanocrystals[J]. Chem Mater，2023，35(10)： 3998-4006.
     [54]Norouzi M，Nazari B，Miller DW.Injectable hydrogel-based drug delivery systems for local cancer therapy[J]. Drug Discov Today，2016，21(11)： 1835-1849.
     [55]Panda S，Bhol CS，Bhutia SK，et al. PEG-PEI-modified gated N-doped mesoporous carbon nanospheres for pH/NIR light-triggered drug release and cancer phototherapy[J]. J Mater Chem B，2021，9(17)： 3666-3676.
     [56]Bitoque DB，Rosa DA Costaa M，Silva GA.Insights on the intracellular trafficking of PDMAEMA gene therapy vectors[J]. Mater Sci Eng C Mater Biol Appl，2018，93：277-288.
     [57]Zai W，Chen W，Wu Z，et al. Targeted interleukin-22 gene delivery in the liver by polymetformin and penetratin-based hybrid nanoparticles to treat nonalcoholic fatty liver disease[J]. ACS Appl Mater Interfaces，2019，11(5)： 4842-4857.
     [58]Li H，Kim Y，Jung H，et al. Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy[J]. Chem Soc Rev，2022，51(21)： 8957-9008.
     [59]Shi Y，Van Der Meel R，Chen X，et al. The EPR effect and beyond：strategies to improve tumor targeting and cancer nanomedicine treatment efficacy[J]. Theranostics，2020，10(17)：7921-7924.
     [60]Akinc A，Maier MA，Manoharan M，et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs[J]. Nat Nanotechnol，2019，14(12)： 1084-1087.
     [61]Gustà MF，Edel MJ，Salazar VA，et al. Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles[J]. Front Immunol，2023，14：1128582.
     [62]Lee K，Davis B，Wang X，et al. Nanoparticle-decorated biomimetic extracellular matrix for cell nanoencapsulation and regulation[J]. Angew Chem Int Ed Engl，2023， 62(31)：e202306583.
     [63]Debacker AJ，Voutila J，Catley M，et al. Delivery of oligonucleotides to the liver with galNAc： from research to registered therapeutic drug[J]. Mol Ther，2020，28(8)：1759-1771.
     [64]Pursell N，Gierut J，Zhou W，et al. Inhibition of glycogen synthase II with RNAi prevents liver injury in mouse models of glycogen storage diseases[J]. Mol Ther，2018，26(7)：1771-1782.
     [65]De Souza R，Picola IPD，Shi Q，et al. Diethylaminoethyl-chitosan as an efficient carrier for siRNA delivery：improving the condensation process and the nanoparticles properties[J]. Int J Biol Macromol，2018，119：186-197.
     [66]Hejl A，RUZIka J，KapcalovVá M，et al. Adjusting the chemical and physical properties of hydrogels leads to improved stem cell survival and tissue ingrowth in spinal cord injury reconstruction： a comparative study of four methacrylate hydrogels[J]. Stem Cells Dev，2013，22(20)：2794-2805.
     [67]mmL C，Drury WJ， 3RD， Knerr L，et al. Targeted delivery of antisense oligonucleotides to pancreatic β-cells[J]. Sci Adv，2018，4(10)： eaat3386.
     [68]Shiraishi Y，Adachi T，Cacicedo JM，et al. Development of a high-yield，high-quality purification process for adeno-associated virus vectors that can be used in vivo without ultracentrifugation：application to a lung endothelial cell-targeted adeno-associated virus[J]. Faseb J，2022，36(12)：e22653.
     [69]Zhang WW，Li L，Li D，et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine)：12 years in the clinic[J]. Hum Gene Ther，2018，29(2)：160-179.
     [70]Lowenstein PR，Castro MG.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors：from mice to clinical trials for glioma patients [J]. Clin Immunol，2018，189：43-51.
     [71]Durinikova E，Plava J，Tyciakova S，et al. Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment[J]. Cancer Gene Ther，2018，25(11-12)： 285-299.
     [72]Kayashima H，Toshima T，Okano S，et al. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice[J]. J Immunol，2010，185(1)： 698-708.
     [73]Lu S，Li L，Luo Y，et al. A multicenter， open-label， randomized phase Ⅱ controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer[J]. J Thorac Oncol，2015，10(1)： 206-211.
     [74]Pan X，Liang L，Si R，et al. Discovery of novel anti-angiogenesis agents.Part 10：multi-target inhibitors of VEGFR-2， Tie-2 and EphB4 incorporated with 1，2，3-triazol[J]. Eur J Med Chem，2019， 163：1-9.
     [75]Ries S，Korn WM.ONYX-015：mechanisms of action and clinical potential of a replication-selective adenovirus[J]. Br J Cancer，2002，86(1)： 5-11.
     [76]Ip WH，Dobner T.Cell transformation by the adenovirus oncogenes E1 and E4[J]. FEBS Lett，2020，594(12)：1848-1860.
     [77]Blair HA.Valoctocogene roxaparvovec：first approval[J]. Drugs，2022，82(14)：1505-1510.
     [78]Iorio A，Krishnan S，Myrén KJ，et al. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products： comparisons of efficacy and weekly factor consumption[J]. J Med Econ，2017，20(4)： 337-344.
     [79]Sardh E， Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria[J]. J Intern Med，2022，291(5)：593-610.
     [80]Montioli R，Bellezza I，Desbats MA，et al. Deficit of human ornithine aminotransferase in gyrate atrophy：molecular，cellular，and clinical aspects [J]. Biochim Biophys Acta Proteins Proteom，2021，1869(1)：140555.
     [81]Ritter JK，Kessler FK，Thompson MT，et al. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes：evidence for both genetic and environmental influences[J]. Hepatology，1999，30(2)：476-484.
     [82]Miravitlles M，Dirksen A，Ferrarotti I，et al. European respiratory society statement： diagnosis and treatment of pulmonary disease in α(1)-antitrypsin deficiency[J]. Eur Respir J，2017，50(5)： 1700610.
     [83]Brantly ML，Chulay JD，Wang L，et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy[J]. Proc Natl Acad Sci USA，2009，106(38)： 16363-16368.
     [84]Cai H，Cheng X，Wang XP.ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a mouse model of Wilson′s disease[J]. Hepatology，2022，76(4)：1046-1057.
     [85]Hair P，Cameron F，Mckeage K.Mipomersen sodium：first global approval[J]. Drugs，2013，73(5)：487-493.
     [86]Ray KK，Wright RS，Kallend D，et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med，2020，382(16)：1507-1519.
     [87]Graham MJ，Lee RG，Brandt TA，et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides[J]. N Engl J Med，2017，377(3)：222-232.
     [88]Viney NJ，Van Capelleveen JC，Geary RS，et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a)：two randomised，double-blind，placebo-controlled，dose-rangingtrials[J]. Lancet，2016，388(10057)：2239-2253.
     [89]Yu RZ，Graham MJ，Post N，et al. Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice[J]. Mol Ther Nucleic Acids，2016，5(5)：e317.
     [90]Greig JA，Limberis MP，Bell P，et al. Nonclinical pharmacology/toxicology study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a mouse model of homozygous familial hypercholesterolemia[J]. Hum Gene Ther Clin Dev，2017，28(1)：28-38.
     [91]Greig JA， Limberis MP， Bell P， et al. Non-clinical study examining AAV8. TBG. hLDLR vector-associated toxicity in Chow-Fed Wild-Type and LDLR (+/-) rhesus macaques[J]. Hum Gene Ther Clin Dev， 2017， 28(1)：39-50.
     [92]Yl-Herttuala S. Endgame：glybera finally recommended for approval as the first gene therapy drug in the European union[J]. Mol Ther，2012，20(10)：1831-1832.
     [93]Tolmachov OE.Self-focusing therapeutic gene delivery with intelligent gene vector swarms：intra-swarm signalling through receptor transgene expression in targeted cells[J]. Artif Intell Med，2015，63(1)：1-6.
     [94]Zhi D，Zhao Y，Cui S， et al. Conjugates of small targeting molecules to non-viral vectors for the mediation of siRNA [J]. Acta Biomater，2016， 36：21-41.

快速检索引用检索图表检索高级检索